Sommaire

• • ·Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study

    Page :563-566

    David J. Moliterno, PARAGON B International Steering Committee ∗

    Résumé Résumé
• • ·Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction

    Page :567-576

    Frank A. Sloan, Peter J. Rankin, David J. Whellan, Christopher J. Conover

    Résumé Résumé
• • ·Statins: Effective antiatherosclerotic therapy

    Page :577-583

    Roger S. Blumenthal

    Résumé Résumé
• • ·β-Blocker improvement in diastolic performance: The yin and yang of ventricular function changes

    Page :584-586

    Eric J. Eichhorn, Paul A. Grayburn

    
• • ·Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan

    Page :587-595

    Gordon W. Moe, Jean L. Rouleau, Lynne Charbonneau, Guy Proulx, J.Malcolm O. Arnold, Christian Hall, Jacques de Champlain, Aiala Barr, Pierre Sirois, Milton Packer

    Résumé Résumé
• • ·β-Blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol

    Page :596-608

    Soccorso Capomolla, Oreste Febo, Marco Gnemmi, Giorgio Riccardi, Cristina Opasich, Angelo Caporotondi, Andrea Mortara, GianDomenico Pinna, Franco Cobelli

    Résumé Résumé
• • ·Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

    Page :609-617

    Christopher B. Granger, Georg Ertl, Jerzy Kuch, Aldo P. Maggioni, John McMurray, Jean-Lucien Rouleau, Lynn Warner Stevenson, Karl Swedberg, James Young, Salim Yusuf, Robert M. Califf, Bradley A. Bart, Peter Held, Eric L. Michelson, Mary Ann Sellers, Gunilla Ohlin, Rodney Sparapani, Marc A. Pfeffer

    Résumé Résumé
• • ·Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension

    Page :618-623

    Antonio Augusto Lopes, Nair Yukie Maeda, Rilvani Cavalcante Gonçalves, Sérgio Paulo Bydlowski

    Résumé Résumé
• • ·Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study

    Page :624-631

    M. Echemann, F. Zannad, S. Briançon, Y. Juillière, P.M. Mertès, J.M. Virion, J.P. Villemot

    Résumé Résumé
• • ·Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries

    Page :632-637

    Evelyn Regar, Frank Werner, Johannes Rieber, Karl Theisen, Harald Mudra, Voker Klauss, Uwe Siebert

    
• • ·Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: Immediate and 2-year long-term follow-up

    Page :638-642

    Sang-Wook Kim, Myeong-Ki Hong, Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park

    
• • ·Role of intracoronary ultrasound after high-pressure stent implantation

    Page :643-648

    James W. Choi, Gil M. Vardi, Sheridan N. Meyers, Michelle A. Parker, Lynne M. Goodreau, Charles J. Davidson

    
• • ·Sex differences in coronary artery size assessed by intravascular ultrasound

    Page :649-652

    Stuart E. Sheifer, Michael R. Canos, Kevin P. Weinfurt, Umesh K. Arora, Farrell O. Mendelsohn, Bernard J. Gersh, Neil J. Weissman

    Résumé Résumé
• • ·Three-dimensional helical computed tomographic angiography in neonates and infants with complex congenital heart disease

    Page :653-660

    Teruhiro Kawano, Masahiro Ishii, Junichi Takagi, Yasuki Maeno, Genju Eto, Yoko Sugahara, Takeshi Toshima, Hiroshi Yasunaga, Takemi Kawara, Kageshige Todo, Hirohisa Kato

    Résumé Résumé
• • ·Peripheral resistance vessel dysfunction in Marfan syndrome

    Page :661-666

    Motoyuki Nakamura, Shigehiro Itoh, Shinji Makita, Atsushi Ohira, Naoshi Arakawa, Katsuhiko Hiramori

    Résumé Résumé
• • ·Vasodilation with felodipine in chronic asymptomatic aortic regurgitation

    Page :667-674

    Lars Søndergaard, Jan Aldershvile, Per Hilderbrandt, Henning Kelbæk, Freddy Ståhlberg, Carsten Thomsen

    Résumé Résumé
• • ·Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material

    Page :675-683

    Jucyléa Cwajg, Feng Xie, Edward O'Leary, David Kricsfeld, Howard Dittrich, Thomas R. Porter

    Résumé Résumé
• • ·Signal-averaged P-wave abnormalities and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation

    Page :684-689

    Naoko Ishimoto, Makoto Ito, Masahiko Kinoshita

    Résumé Résumé
• • ·Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias

    Page :690-695

    Richard I. Fogel, John M. Herre, Harry A. Kopelman, Peter R. Kowey, Richard G. Trohman, Naomi Fineberg, Eric N. Prystowsky

    Résumé Résumé
• • ·Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

    Page :696-703

    Mary A. Mascelli, Neal S. Kleiman, Stanley J. Marciniak, Lakshmi Damaraju, Harlan F. Weisman, Robert E. Jordan

    Résumé Résumé
• • ·Benefits of magnesium in acute myocardial infarction: Timing is crucial

    Page :703

    Geeta Gyamlani, Chirag Parikh, Arvind G. Kulkarni

    
• • ·Alcohol consumption and plasminogen activator inhibitor type 1: The national heart, lung, and blood Institute family heart study

    Page :704-709

    Luc Djoussé, James S. Pankow, Donna K. Arnett, Yuqing Zhang, Yuling Hong, Michael A. Province, R. Curtis Ellison

    Résumé Résumé
• • ·Right ventricular function in patients with first inferior myocardial infarction: Assessment by tricuspid annular motion and tricuspid annular velocity

    Page :710-715

    Mahbubul Alam, Johan Wardell, Eva Andersson, Bassem A. Samad, Rolf Nordlander

    Résumé Résumé
• • ·Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals

    Page :716-722

    Hiroyuki Okura, Hiroo Inoue, Miyo Tomon, Shoji Nishiyama, Tadashi Yoshikawa, Kiyoshi Yoshida, Junichi Yoshikawa

    Résumé Résumé
• • ·Aortic root dilatation among young competitive athletes: Echocardiographic screening of 1929 athletes between 15 and 34 years of age

    Page :723-728

    Norimitsu Kinoshita, Jun Mimura, Chiyomi Obayashi, Fuminori Katsukawa, Shohei Onishi, Hajime Yamazaki

    Résumé Résumé
• • ·Changes in lipoprotein(a) concentration after orthotopic heart transplantation

    Page :729-733

    David DeNofrio, Shashank Desai, Daniel J. Rader, Gene Chang, Michael P. Kelley, Michael A. Acker, Evan Loh

    Résumé Résumé
• • ·Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?

    Page :734-738

    Jerome D. Cohen, John H. Drury, Jamie Ostdiek, Jane Finn, B.R. Veerendra Babu, Gregory Flaker, Kathy Belew, Thomas Donohue, Arthur Labovitz

    Résumé Résumé
• • ·Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease

    Page :739-744

    Rita F. Redberg, Masami Nishino, Doff B. McElhinney, Michael W. Dae, Elias H. Botvinick

    Résumé Résumé
• • ·Introduction

    Page :S131

    Robert Califf, Monica Shah

    
• • ·Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials

    Page :S133

    Robert Temple

    
• • ·Challenges in the conduct and interpretation of phase II (pilot) randomized trials

    Page :S136

    Salim Yusuf

    
• • ·The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials

    Page :S143

    Christopher M. O'Connor, Wendy A. Gattis, Thomas J. Ryan

    
• • ·Economic end points in phase II trials

    Page :S155

    Daniel B. Mark, Tracey A. Simons

    
• • ·Select-drop designs in clinical trials

    Page :S158

    Susan S. Ellenberg

    
• • ·Sample size and interim analysis issues for dose selection

    Page :S161

    Kerry L. Lee

    
• • ·Equivalence and noninferiority trials

    Page :S166

    Jay P. Siegel

    
• • ·Design and interpretation of equivalence trials

    Page :S171

    Thomas R. Fleming

    
• • ·Estimating the distribution of quality-adjusted life with censored data

    Page :S177

    Anastasios A. Tsiatis

    
• • ·Chronic ischemic heart disease

    Page :S182

    Michael Gent, Robert M. Califf

    
• • ·Acute ischemic heart disease

    Page :S189

    Christopher B. Granger, Allan Skene

    
• • ·Surrogate end points in cardiovascular disease trials

    Page :S193

    Thomas R. Fleming

    
• • ·An FDA perspective on antiarrhythmic drugs in phase II trials

    Page :S197

    Raymond Lipicky

    
• • ·The development of antiarrhythmic drugs

    Page :S200

    Lloyd Fisher

    
• • ·Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure

    Page :S202

    Milton Packer

    
• • ·Design of phase II trials in congestive heart failure

    Page :S207

    David L. DeMets